NZ630121A - Process for purifying recombinant plasmodium falciparum circumsporozoite protein - Google Patents

Process for purifying recombinant plasmodium falciparum circumsporozoite protein

Info

Publication number
NZ630121A
NZ630121A NZ630121A NZ63012113A NZ630121A NZ 630121 A NZ630121 A NZ 630121A NZ 630121 A NZ630121 A NZ 630121A NZ 63012113 A NZ63012113 A NZ 63012113A NZ 630121 A NZ630121 A NZ 630121A
Authority
NZ
New Zealand
Prior art keywords
falciparum circumsporozoite
circumsporozoite protein
rcsp
plasmodium falciparum
protein
Prior art date
Application number
NZ630121A
Other languages
English (en)
Inventor
Jeffrey Allen
Greg Cantin
Ryan Haverstock
Original Assignee
Pfenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfenex Inc filed Critical Pfenex Inc
Publication of NZ630121A publication Critical patent/NZ630121A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ630121A 2012-05-01 2013-04-22 Process for purifying recombinant plasmodium falciparum circumsporozoite protein NZ630121A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641105P 2012-05-01 2012-05-01
US13/844,261 US9169304B2 (en) 2012-05-01 2013-03-15 Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
PCT/US2013/037656 WO2013165732A1 (en) 2012-05-01 2013-04-22 Process for purifying recombinant plasmodium falciparum circumsporozoite protein

Publications (1)

Publication Number Publication Date
NZ630121A true NZ630121A (en) 2016-06-24

Family

ID=49514758

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630121A NZ630121A (en) 2012-05-01 2013-04-22 Process for purifying recombinant plasmodium falciparum circumsporozoite protein

Country Status (16)

Country Link
US (2) US9169304B2 (enExample)
EP (1) EP2844666B1 (enExample)
JP (1) JP6238967B2 (enExample)
KR (1) KR102087461B1 (enExample)
CN (1) CN104379596B (enExample)
AR (1) AR090900A1 (enExample)
AU (1) AU2013256757B2 (enExample)
BR (1) BR112014027019B1 (enExample)
CA (1) CA2870198C (enExample)
MX (1) MX352093B (enExample)
MY (1) MY166380A (enExample)
NZ (1) NZ630121A (enExample)
SG (1) SG11201407108TA (enExample)
TW (1) TWI630213B (enExample)
WO (1) WO2013165732A1 (enExample)
ZA (1) ZA201407420B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2015105551A1 (en) * 2014-01-09 2015-07-16 Kentucky Bioprocessing, Inc. Method of purifying monoclonal antibodies
CA2944407A1 (en) * 2014-03-28 2015-10-01 Conjugon, Inc. Preparation of small colony variants of therapeutic bacteria
CN113444183B (zh) 2014-12-01 2025-06-17 佩利肯科技控股公司 用于肽生产的融合伴侣
CN109966319B (zh) * 2017-12-22 2022-11-22 四川好医生攀西药业有限责任公司 一种康复新液的原料及其制备方法和应用
CN108559721A (zh) * 2018-05-15 2018-09-21 北京师范大学 一种净化空气的复合微生物菌剂及其应用
US20230241194A1 (en) * 2020-06-29 2023-08-03 Michael Theisen Pre-erythrocytic malaria vaccines

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2145092B (en) 1983-01-28 1988-04-07 Univ New York Protective peptide antigen
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4830962A (en) 1984-02-09 1989-05-16 Cetus Corporation Recombinant diphtheria toxin fragments
ZA855232B (en) 1984-07-23 1986-02-26 Univ New York Protective peptide antigen corresponding to plasmodium falciparum circumsporozoite protein
ZA856655B (en) 1984-09-12 1986-04-30 Univ New York Cross-reactive and protective epitopes of circumsporozoite proteins
US5178861A (en) 1984-09-12 1993-01-12 New York University Cross-reactive and protective epitopes of circumsporozoite proteins
US4695462A (en) 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US4695455A (en) 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8517071D0 (en) 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
AU590599B2 (en) 1985-07-12 1989-11-09 New York University Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein
CA1340373C (en) 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
EP0252588A3 (en) 1986-05-12 1989-07-12 Smithkline Beecham Corporation Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
EP0278941A1 (en) 1987-01-30 1988-08-17 Smithkline Biologicals S.A. Expression of the P. falciparum circumsporozoite protein by yeast
KR0168039B1 (ko) 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5128130A (en) 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
AU625713B2 (en) 1988-02-19 1992-07-16 Microgenesys, Inc. Method for producing recombinant protein derived from the circumsporozoite gene of plasmodium falciparum
US5055294A (en) 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
GB8812214D0 (en) 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5028425A (en) 1988-07-07 1991-07-02 The United States Of America As Represented By The Department Of Health And Human Services Synthetic vaccine against P. falciparum malaria
DE768377T1 (de) * 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US6043057A (en) 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
KR910700352A (ko) 1988-12-21 1991-03-14 스미스클라인 바이올로지칼즈(s.a.) 곤충 세포내에서 플라스모듐 서컴스포로 조이트 단백질의 발현
WO1990009444A1 (en) 1989-02-10 1990-08-23 Genesit Oy A method for producing pertussis toxin subunits
US7232671B2 (en) 1989-02-15 2007-06-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
NZ233255A (en) 1989-04-11 1993-02-25 Chiron Corp Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope
ES2078258T3 (es) 1989-04-28 1995-12-16 Sclavo Spa Mutantes de toxina pertussica, cepas de bordetella capaces de producir tales mutantes y su uso en el desarrollo de vacunas antipertussicas.
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
US5169760A (en) 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
ES2058821T3 (es) 1989-11-28 1994-11-01 Wellcome Found Vacunas.
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
WO1992017204A1 (en) 1991-04-01 1992-10-15 The United States Of America, Represented By The Secretary, United States Department Of Commerce Circumsporozoite protein of plasmodium reichenowi and vaccine for human malaria
US5935580A (en) 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
ATE156710T1 (de) 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
DK0725653T3 (da) 1993-10-05 2004-10-11 Celltech Pharmaceuticals Ltd Vaccinepræparater
GB9406492D0 (en) 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
US20040214157A1 (en) 1994-06-29 2004-10-28 Simon C. Burton Chromatographic resins and methods for using same
US5652348A (en) 1994-09-23 1997-07-29 Massey University Chromatographic resins and methods for using same
WO1996010089A1 (en) 1994-09-29 1996-04-04 Ajinomoto Co., Inc. Modification of peptide and protein
US5932714A (en) 1995-02-23 1999-08-03 Connaught Laboratories Limited Expression of gene products from genetically manipulated strains of Bordetella
SE9600590D0 (sv) 1996-02-19 1996-02-19 Pharmacia Biotech Ab Sätt för kromatografisk separation av peptider och nukleinsyra samt ny högaffin jonbytesmatris
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
EP1860192A1 (en) 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
AU765801B2 (en) 1999-02-18 2003-10-02 Rmf Dictagene S.A. Malaria vaccine
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6942866B2 (en) * 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU2001293074A1 (en) 2000-09-25 2002-04-08 Walter Reed Army Institute Of Research Human liver cell line
US7781186B2 (en) 2000-09-25 2010-08-24 The United States Of America As Represented By The Secretary Of The Army Screening methods using normal human liver cell line
US7363166B2 (en) * 2001-03-30 2008-04-22 Council Of Scientific & Industrial Research Computational method for the identification of candidate proteins useful as anti-infectives
SE0104353D0 (sv) 2001-12-19 2001-12-19 Amersham Biosciences Ab Separation method
WO2004041857A2 (en) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20040067880A1 (en) 2002-10-04 2004-04-08 Kuo Macus Tien Prodrug therapy of liver diseases using receptor-mediated delivery of malarial circumsporozoite protein as a carrier
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
AU2003285932A1 (en) 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
EP1573012B1 (en) 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
US7670631B2 (en) 2003-03-12 2010-03-02 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
US8399217B2 (en) 2003-03-14 2013-03-19 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
WO2005052151A1 (en) 2003-11-19 2005-06-09 Dow Global Technologies Inc. Improved protein expression systems
EP2327718B1 (en) 2003-11-21 2016-03-23 Pfenex, Inc. Improved expression systems with SEC-system secretion
WO2005063805A1 (en) 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
KR20120076377A (ko) 2004-01-16 2012-07-09 다우 글로벌 테크놀로지스 엘엘씨 슈도모나스 플루오레센스에서의 포유류 단백질의 발현
EP2412816B1 (en) 2004-07-26 2014-12-03 Pfenex Inc. Process for improved protein expression by strain engineering
US7273963B2 (en) 2004-08-20 2007-09-25 Kmt Hepatech, Inc. Malarial animal model having a chimeric human liver
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
CA2593643C (en) 2005-01-18 2016-03-22 Walter Reed Army Institute Of Research A plasmodium vivax hybrid circumsporozoite protein and vaccine
EP1754717A1 (en) 2005-08-19 2007-02-21 Université de Lausanne Antigenic peptides and their use
AP2008004448A0 (en) 2005-09-30 2008-04-30 Seattle Biomedical Res Inst Plasmodium liver stage antigens
US7749519B2 (en) 2005-12-09 2010-07-06 Kim Lee Sim Unique DNA and polypeptide sequences based on the circumsporozoite protein of Plasmodium vivax
BRPI0711878A2 (pt) 2006-05-30 2012-01-10 Dow Global Technologies Inc método de otimização do códon
CA2677179C (en) 2007-01-31 2016-02-16 Dow Global Technologies Inc. Bacterial leader sequences for increased expression
CA2685326A1 (en) 2007-04-27 2008-11-06 Dow Global Technologies Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5508266B2 (ja) 2007-08-13 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
WO2009114202A2 (en) 2008-03-14 2009-09-17 The United States Of America As Represented By The Secretary Of The Navy Vaccine and immunization method using plasmodium antigen 2
WO2010008764A1 (en) 2008-06-23 2010-01-21 Dow Global Technologies Inc. Pseudomonas fluorescens strains for production of extracellular recombinant protein
ES2699434T3 (es) 2008-10-31 2019-02-11 Wyeth Llc Purificación de proteínas ácidas utilizando cromatografía de hidroxiapatita cerámica
US8063193B2 (en) 2009-03-27 2011-11-22 Abbott Laboratories Nucleotide and amino acid sequences encoding an exported protein 1 derived from Plasmodium vivax and uses thereof
KR101857825B1 (ko) 2010-03-04 2018-05-14 피페넥스 인크. 변성 없이 가용성 재조합 인터페론 단백질을 제조하는 방법
MX343356B (es) 2010-03-30 2016-11-03 Pfenex Inc * Toxinas proteicas recombinantes de alto nivel de expresion.
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
EP2385107B1 (en) 2010-05-03 2016-08-24 Institut Pasteur Lentiviral vector based immunological compounds against malaria
WO2012154199A1 (en) 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Soluble recombinant plasmodium falciparum circumsporozoite protein
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein

Also Published As

Publication number Publication date
MX2014013124A (es) 2015-02-05
AU2013256757B2 (en) 2017-02-16
MY166380A (en) 2018-06-25
EP2844666A1 (en) 2015-03-11
EP2844666A4 (en) 2015-11-04
US20140051841A1 (en) 2014-02-20
AR090900A1 (es) 2014-12-17
CN104379596B (zh) 2018-05-29
TWI630213B (zh) 2018-07-21
US9849177B2 (en) 2017-12-26
TW201348250A (zh) 2013-12-01
AU2013256757A1 (en) 2014-10-30
US20160051677A1 (en) 2016-02-25
BR112014027019B1 (pt) 2022-09-06
CA2870198C (en) 2019-12-03
BR112014027019A2 (pt) 2017-07-11
US9169304B2 (en) 2015-10-27
CA2870198A1 (en) 2013-11-07
SG11201407108TA (en) 2014-11-27
JP2015517464A (ja) 2015-06-22
EP2844666B1 (en) 2019-07-17
KR20150027743A (ko) 2015-03-12
CN104379596A (zh) 2015-02-25
MX352093B (es) 2017-11-08
KR102087461B1 (ko) 2020-03-10
JP6238967B2 (ja) 2017-11-29
ZA201407420B (en) 2016-10-26
WO2013165732A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
NZ630121A (en) Process for purifying recombinant plasmodium falciparum circumsporozoite protein
HK1202885A1 (en) Silicon-containing fumaric acid esters
AR092456A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
MX360044B (es) Etanercept plegado correctamente con alta pureza y un rendimiento excelente.
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
NZ711445A (en) Fusion immunomodulatory proteins and methods for making same
MX354516B (es) Vectores que codifican el factor de viabilidad de conos derivado de bastones.
MX2014002087A (es) Formulaciones piretroides.
WO2012141978A3 (en) Formulations with reduced viscosity
JO3092B1 (ar) مركب لتحفيز مسيطر عليه للمبيض
MX368142B (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
EA201391488A1 (ru) Композиции со сниженной вязкостью
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
MX358161B (es) Analogos de hormona paratiroidea y usos para los mismos.
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
WO2012057529A3 (en) Method for purifying human granulocyte-colony stimulating factor from recombinant e. coli
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
EA201290565A1 (ru) Получение белка гемагглютинин-нейраминидазы в микроводорослях
EA201691754A1 (ru) Рекомбинантный микроорганизм, экспрессирующий аналог авермектина, и его применение
PL2919801T3 (pl) Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
IL238897A0 (en) Growth hormone-albumin fusion proteins, their formulation and use
MY171770A (en) An apparatus for continuous separation of valine and a method for continuous separation of valine using the same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2018 BY CPA GLOBAL

Effective date: 20170311

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2019 BY CPA GLOBAL

Effective date: 20180309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2020 BY CPA GLOBAL

Effective date: 20190307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2021 BY CPA GLOBAL

Effective date: 20200306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2022 BY CPA GLOBAL

Effective date: 20210312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2023 BY CPA GLOBAL

Effective date: 20220310

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 APR 2024 BY CPA GLOBAL

Effective date: 20230309

LAPS Patent lapsed